Venture Life Group PLC Board Change (9594Z)
19 Mai 2023 - 8:00AM
UK Regulatory
TIDMVLG
RNS Number : 9594Z
Venture Life Group PLC
19 May 2023
19(th) May 2023
VENTURE LIFE GROUP PLC
("Venture Life", "VLG" or the "Company")
Board change
Venture Life (AIM: VLG), a leader in developing, manufacturing
and commercialising products for the self-care market, announces
that Mrs Sharon Daly (nee Collins) will be leaving the Company on 3
August 2023 to pursue
other opportunities and hence, will cease to be a director .
Sharon co-founded Venture Life in 2010 and since then, has made
a significant contribution to the growth of the business. She has
been pivotal in Venture Life's journey of growth over the years,
and we would like to thank her for that.
Sharon leaves the business having played a significant role in
taking Venture Life from a start up to the substantially bigger
business that it is today, listed on AIM.
We would like to express our gratitude and thanks to Sharon for
the hard work and support she has given to the business, and wish
her the very best in her new endeavours.
Sharon will affect a smooth handover of her responsibilities
before she finally leaves the business. At this point, Sharon's
role of Chief Commercial Officer will not be replaced on the Board,
but her role will be restructured across the existing team within
the business, bolstered, if necessary, in due course, with any
additional resource identified as needed.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cenkos Securities plc (Nomad and Joint Broker) +44 (0) 20 7397
8900
Stephen Keys / Camilla Hume (Corporate Finance)
Russell Kerr / Michael Johnson (Sales)
Singer Capital Markets (Joint Broker)
Shaun Dobson / Alaina Wong (Corporate Finance) +44 (0) 20
74963000
Jonathan Dighe (Sales)
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in the UK, Italy,
The Netherlands and Sweden, the Group's product portfolio includes
some key products such as the UltraDEX and Dentyl oral care product
ranges, the Balance Activ range in the area of women's intimate
healthcare, the Lift and Glucogel product ranges for hypoglycaemia,
Gelclair and Pomi-T for oncology support, products for fungal
infections and proctology, and dermo-cosmetics for addressing the
signs of ageing. Its products are sold in over 90 countries
worldwide.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK and The Netherlands
these are supplied direct by the company to retailers, elsewhere
they are supplied by the Group's international distribution
partners.
Through its two Development & Manufacturing operations in
Italy and Sweden, the Group also provides development and
manufacturing services to companies in the medical devices and
cosmetic sectors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOAAPMMTMTTBTTJ
(END) Dow Jones Newswires
May 19, 2023 02:00 ET (06:00 GMT)
Venture Life (LSE:VLG)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Venture Life (LSE:VLG)
Historical Stock Chart
Von Jan 2024 bis Jan 2025